Showing results (2131-2140 of 2,239) with videos related to
Sort By:
Pageof 224
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG StudyJin-Ji Yang, Yan Zhang, Lin Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJonathan D Spicer, Tina Cascone, Murry W Wynes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.Environmental Microbiology|December 5, 2019
The false smut pathogen Ustilaginoidea virens requires rice stamens for false smut ball formationJing Fan, Jie Liu, Zhi-You Gong, et al.JTO Clinical and Research Reports|May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCQing Zhou, Ross A Soo, Gee-Chen Chang, et al.The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.Cell Reports. Medicine|January 19, 2023
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world studyHan-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, et al.The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.Pageof 224